Spark Therapeutics (ONCE) Research Coverage Started at Credit Suisse Group

Equities research analysts at Credit Suisse Group started coverage on shares of Spark Therapeutics (NASDAQ:ONCE) in a report released on Wednesday. The brokerage set an “outperform” rating and a $61.00 price target on the biotechnology company’s stock. Credit Suisse Group’s price objective suggests a potential upside of 18.38% from the stock’s current price.

Several other research analysts also recently commented on ONCE. SunTrust Banks set a $101.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, October 16th. Raymond James Financial set a $66.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Cantor Fitzgerald set a $105.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Royal Bank of Canada dropped their price objective on shares of Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating for the company in a research report on Wednesday, November 8th. Finally, BMO Capital Markets set a $67.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $74.45.

Shares of Spark Therapeutics (ONCE) traded up $0.21 on Wednesday, hitting $51.53. The stock had a trading volume of 760,701 shares, compared to its average volume of 970,830. The firm has a market cap of $1,910.00 and a P/E ratio of -7.16. Spark Therapeutics has a fifty-two week low of $41.06 and a fifty-two week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.11). The business had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The firm’s revenue was up 45.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.07) earnings per share. equities analysts predict that Spark Therapeutics will post -7.55 EPS for the current fiscal year.

In other Spark Therapeutics news, insider Daniel Faga sold 7,500 shares of the company’s stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $80.96, for a total transaction of $607,200.00. Following the completion of the sale, the insider now owns 6,000 shares in the company, valued at approximately $485,760. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $83.30, for a total transaction of $416,500.00. Following the sale, the insider now owns 215,000 shares of the company’s stock, valued at approximately $17,909,500. The disclosure for this sale can be found here. Insiders have sold a total of 62,309 shares of company stock valued at $4,621,085 in the last quarter. Corporate insiders own 7.30% of the company’s stock.

Institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. raised its position in shares of Spark Therapeutics by 15.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after acquiring an additional 241,016 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Spark Therapeutics by 6.0% in the 3rd quarter. Ameriprise Financial Inc. now owns 207,360 shares of the biotechnology company’s stock valued at $18,489,000 after buying an additional 11,785 shares in the last quarter. BlackRock Inc. increased its position in shares of Spark Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after buying an additional 213,520 shares in the last quarter. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Spark Therapeutics in the 3rd quarter valued at $5,286,000. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Spark Therapeutics in the 3rd quarter valued at $13,519,000. Institutional investors own 94.91% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Spark Therapeutics (ONCE) Research Coverage Started at Credit Suisse Group” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3143050/spark-therapeutics-once-research-coverage-started-at-credit-suisse-group.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.